Lead candidate identification PK and toxicology studies for antibody project in blueprint neurotherapeutics (BPN) biologics program
Ended Awarded
- Contract number
- 75N95024F00003
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $497,895
Award facts
- Opportunity
-
- 75N95024R00053 Solicitation number
- Contract value 9% obligated
-
- $497,895.00 Current, with exercised options
- $5,724,344.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541512 Computer Systems Design Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Germantown, MD 20875, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a $5,724,344 federal contract award issued by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is a delivery order under the larger "Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders" Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $149.2 million.
The purpose of this contract is to conduct lead candidate identification, pharmacology, and toxicology studies for an antibody project within NINDS's Blueprint Neurotherapeutics (BPN) Biologics Program. ABL, a foreign-owned, for-profit manufacturer of goods, will provide a range of preclinical development services to support this neurological research initiative. The contract does not have a set-aside designation, reflecting ABL's status as a large business in the federal contracting landscape. ABL has extensive experience in supporting the development of vaccines, therapeutics, and diagnostics across various disease areas and federal health agencies through its work on numerous IDVs and grant-funded projects.
Quick answers
Who was awarded contract 75N95024F00003?
75N95024F00003 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute on Drug Abuse (National Institutes of Health) on July 19, 2024.
How much is contract 75N95024F00003 worth?
The government has obligated $497,895 on 75N95024F00003. Its potential value, with all options, is $5,724,344.
Which agency awarded contract 75N95024F00003?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024F00003, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95024F00003 an order under another contract?
Yes. 75N95024F00003 is a delivery order under 75N95022D00023, an indefinite delivery contract, on Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders.
Was contract 75N95024F00003 competed?
The extent of competition for 75N95024F00003 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award